Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238519 · ClinicalTrials.gov registry record · Phase 3
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
A Phase 3 study of Genetic Disease and Familial Hypercholesterolemia, sponsored by Essentia Health.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 2
- Study locations
NCT05238519: Active Phase 3 study of Genetic Disease and Familial Hypercholesterolemia, sponsored by Essentia Health.
NCT05238519 is a Phase 3 study of Genetic Disease and Familial Hypercholesterolemia that is active but no longer recruiting, run by Essentia Health. The registered enrollment target is 300 participants, below the 2,551-participant average among 30 other Genetic Disease trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05238519, a Phase 3 study of Genetic Disease and Familial Hypercholesterolemia, is active but no longer recruiting, sponsored by Essentia Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.
Primary Outcome
Self-report of knowledge of personal history of FH will be assessed at baseline and follow up
Conditions Studied
Interventions
- BEHAVIORAL Motivational interview (MI)
Study Locations (2)
Minnesota
- Aspirus St. Luke's Hospital - Duluth
- Essentia Health - Duluth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What the registry record for NCT05238519 still lists
NCT05238519 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 2,551-participant average among 30 other Genetic Disease trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Motivational interview (MI) is the first listed.
NCT05238519 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05238519 about?
NCT05238519 is a clinical study titled "Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)". The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as ...
What is the current status of trial NCT05238519?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2022-02-15. Estimated completion is 2026-06.
What conditions does trial NCT05238519 study?
This clinical trial studies the following conditions: Genetic Disease, Familial Hypercholesterolemia, Cholesterol, Elevated.
What interventions are being tested in trial NCT05238519?
The interventions under investigation include: Motivational interview (MI) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05238519?
This trial is sponsored by Essentia Health, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05238519 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05238519's enrollment target sits among peer trials
300 14th of 30 higher than 17 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long Term Extension Study in Patients With Primary Hyperoxaluria
ACTIVE NOT RECRUITING · Phase 3
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI